<!-- Shared "Why Now" strategic argument - used by executive brief and RTA -->
<!-- Source of truth: MASTER.md Section 2.1 -->

The timing for CTAP is uniquely favourable due to an unprecedented convergence of enabling factors:

### The 2027 Convergence Window

Three infrastructure maturation timelines converge in 2027â€”creating a unique opportunity that will not recur:

1. **Connect Care Maturation (2020-2024)**: Province-wide Epic deployment completed 2024. The data warehouse now contains 4+ years of longitudinal records across 4.4M Albertans. FHIR API capabilities are proven. This is the first year with sufficient historical depth for population-scale AI training.

2. **AI Capability Threshold (2023-2025)**: Large Language Models crossed the clinical reasoning threshold in 2023-2024. Agentic AI frameworks (multi-agent coordination) matured in 2025. The evidence base for AI in clinical trials now includes 50+ publications validating component-level gains.

3. **Biomanufacturing Capacity (2024-2026)**: PRAIRIE Hub funded 2024. CMPC construction completes 2026 with 70M+ dose/year capacity. Canada's largest pharmaceutical manufacturing capacity comes online precisely when clinical validation infrastructure is needed.

**Waiting is not neutral.** Each year of delay:
- Allows competing centres (Toronto, Vancouver, Montreal) to establish first-mover advantages in AI-enabled trials
- Wastes Connect Care data that could be training AI models now
- Leaves CMPC-manufactured products without local clinical validation pathways
- Risks losing AI talent to better-resourced international programs

### Window Closure Risk

CFI Innovation Fund competitions occur approximately every 3-5 years. If CTAP misses the 2027 competition:
- The next opportunity may not arise until 2030-2032
- Connect Care's first-mover data advantage will have eroded as other provinces complete their EMR integrations
- AI-enabled clinical trials infrastructure will be established elsewhere
- CMPC's first 3-4 years of manufacturing will lack integrated clinical validation capacity

### Enabling Factors

**Provincial Health Data Infrastructure:** Connect Care (Epic-based EMR) is fully deployed across 682 AHS sites, providing province-wide access to 4.4 million Albertan health records with FHIR API capabilities enabling real-time data integration.

**Biomanufacturing Expansion:** The Critical Medicines Production Centre ($200M, 70M+ doses/year by 2026), PRAIRIE Hub ($109.9M pandemic preparedness, 2024), and operational Alberta Cell Therapy Manufacturing create unprecedented manufacturing-to-trials capacity.

**Federal Strategic Alignment:** ACT-AEC (Accelerating Clinical Trials), PRAIRIE Hub, RareKids-CAN, and DHDP ($49M federal + $108M partner + $165M in-kind) provide national network context and matching investment opportunities.

**Institutional Commitment:** The $25M Kipnes Health Research Institute philanthropic investment signals deep institutional commitment, while Forward with Purpose strategic plan prioritizes health/life sciences, AI, and digital innovation.

CFI Innovation Fund 2027 represents a unique opportunity to position Alberta as national leader before competing centres establish similar infrastructure, leveraging existing investments with CFI matching.
